Terns Pharmaceuticals filed an SC TO-T/A amendment this morning, the second iteration of a third-party tender offer document that marks active M&A negotiations for the South San Francisco biotech. The amendment follows an initial SC TO-T filing, indicating terms have shifted since the buyer first disclosed its offer. Terns closed yesterday at $7.82 per share, giving the company a market capitalization near $500 million.

The SC TO-T/A form is not routine disclosure. It appears when a third party amends the terms, timing, or structure of an acquisition offer after initial filing. The document itself is a Schedule TO filed under Section 14(d)(1) of the Securities Exchange Act, required when an acquirer seeks to purchase equity securities through a tender offer. Amendments typically reflect price adjustments, extension of offer periods, or changes to deal conditions following target board negotiation or shareholder feedback. Terns has not yet filed a corresponding DFAN14A solicitation, which would signal board recommendation to accept or reject.

Terns holds a pipeline centered on non-alcoholic steatohepatitis, led by TERN-501, a thyroid hormone receptor beta agonist that completed a Phase 2a trial in December 2023 with 48-week topline data. The company reported statistically significant reduction in liver fat and fibrosis markers, positioning the asset as a potential complement to GLP-1 agonists in metabolic liver disease. Terns also advanced TERN-601, a PPAR-delta/gamma agonist, into Phase 1 trials. The NASH space has seen compressed valuations since Madrigal's resmetirom approval in March 2024 failed to ignite the sector, leaving mid-stage biotechs trading at discounts to historical peer multiples. A tender offer at this stage suggests an acquirer sees durable value in Terns' clinical dataset or believes the market has mispriced the asset's regulatory path.

The timing matters. Terns reported $198 million in cash as of September 30, 2024, sufficient to fund operations into mid-2026 under prior guidance. That runway eliminates distressed sale pressure, meaning any tender offer reflects strategic interest rather than rescue financing. The amendment filing indicates the buyer is refining terms, likely around price per share, minimum tender condition, or regulatory clearance language. The lack of a Terns board response filing suggests the company is either in active negotiation or evaluating multiple expressions of interest. The NASH landscape has consolidated over the past eighteen months, with Viking Therapeutics and Akero Therapeutics both advancing competing assets, while legacy players like Gilead and Novo Nordisk circle earlier-stage programs for pipeline fill.

Operators should track three events over the next 30 to 45 days: a Terns Schedule 14D-9 response, which the board must file within 10 business days of the tender offer becoming effective; any second amendment to the SC TO-T, which would signal continued term negotiation or a competing bid; and insider trading disclosures on Form 4, particularly by Terns' founding management team, which would reveal whether leadership is tendering shares or holding for a higher offer. The company's next earnings call is not scheduled until early February, meaning disclosure will come through SEC filings rather than earnings commentary.

The amended tender offer is the only public fact that matters. Someone is negotiating, and the terms are still moving.